Duration of Catheter Use in Patients with Diabetes Using Continuous Subcutaneous Insulin Infusion: A Review.

Lisa Bonato, Nadine Taleb, Véronique Gingras, Virginie Messier, Fernand Gobeil, Julie Ménard, Jean-Luc Ardilouze, Rémi Rabasa-Lhoret

Journal: Diabetes technology & therapeutics 2018;20(7):506-515

PMID: 29958025

Abstract

Increasing proportions of patients with diabetes use continuous subcutaneous insulin infusion (CSII) therapy mostly due to its clinical efficacy and flexibility for insulin dosing and adjustments. Some challenges are nevertheless associated with this technology. A key and underlooked component of CSII technical difficulties is the subcutaneous catheter used to infuse insulin. Several adverse events (AEs) have been experienced by patients in relation to catheters, such as blockage, kinking, and insertion site reactions, including irritation, infections, lipohypertrophies etc., all of which could compromise the metabolic control. With the objective of minimizing these AEs, recommendations for changing catheters every 2-3 days have historically been provided by manufacturers based on reports derived from small studies and anecdotal data. The aim of this review was to provide an updated analysis of current recommendations and patients' practices in relation to frequency of catheter change. Our main findings are: (1) adequately designed and powered studies investigating optimal catheter wearing time are still lacking; (2) increasing catheter wearing time is generally associated with increased frequency of catheter AEs; (3) however, interpatient variability is large, with some individuals needing to change their catheters every 2-3 days, whereas others probably being able to keep them in place for longer periods without problems. Further research is thus warranted to provide more solid and evidence-based recommendations while exploring personalized approaches at the same time. Increasing catheter wear life without significant side effects is an important goal to simplify CSII therapy and reduce its associated costs and burdens.

Address: 1 Research Platform on obesity, metabolism and diabetes, Institut de Recherches Cliniques de Montréal (IRCM) , Montréal, Québec, Canada .; 2 Department of Biomedical Sciences, Faculty of Medecine, Université de Montréal , Édouard-Montpetit, Montréal, Québec, Canada .; 3 Department of Nutrition, Faculty of Medecine, Université de Montréal , Chemin de la Côte-Sainte-Catherine, Montréal, Québec, Canada .; 4 Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke , Sherbrooke, Québec, Canada .; 5 Diabetes, obesity and cardiovscular complications axis, Research Center of the Centre Hospitalier Universitaire de Sherbrooke , Sherbrooke, Québec, Canada .; 6 Endocrine Division, Department of Medicine, Faculty of Medicine and Health Sciences, Université de Sherbrooke , Sherbrooke, Québec, Canada .; 7 Montréal Diabetes Research Center , Saint-Denis Montréal, Québec, Canada .
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.